affinity (apparent KD)
With our iQue Screener PLUS flow cytometer we screen antibodies for on-cell binding to identify massive panels of antigen-specific antibodies for further interrogation.
The iQue achieves faster assay throughput than traditional flow cytometers by sampling only microliters from each well and delivering an air-gap-delimited flow of samples to the detectors.
The iQue Screener PLUS converts the traditional low throughput, time-consuming flow cytometry approach into a high throughput process.
The end result is a data-rich snapshot of the molecular events occurring in each well that can take less than five minutes for a 96-well plate.
Real time label-free binding analyses have introduced a new era in antibody screening and characterization, quickly. Abveris employs Carterra Surface Plasmon Resonance (SPR) and Octet Bio-Layer Interferometry (BLI) for detection of label-free molecular interactions.
Carterra SPR and Octet BLI are fully integrated into our custom monoclonal antibody development so that we can screen hundreds of monoclonal antibody candidates for desired binding specificity and kinetics suited for your intended application(s).
Both the Carterra and Octet based analyses are stand-alone services available to partners interested in binding kinetic analyses.
Species Cross-Reactivity Assessments
Kinetics, Affinity, KD determination
Epitope Binning, Antibody Pairing
Ligand Blocking Analyses
Rapid Antibody Quantitation
Enzyme-Linked Immunosorbent Assays (ELISAs) are one of the most common and transferrable screening formats employed for antibody-based assays.
ELISA-type assays are especially beneficial for soluble or secreted targets. In particular, they’re useful for the development of critical reagents or PK or ADA assays to support clinical development or for the discovery and characterization of antibodies against soluble therapeutic targets.
- High-throughput, highly automated platform
- Experience with diverse assay formats, including indirect ELISA, capture ELISA, bridging ELISA, competition ELISA, and more.
The Beacon platform by Berkeley Lights is a disruptive, best-in-industry technology for single B-cell screening. It enables high resolution screening of antibody secreting B-cells with a throughput and timeline that was unimaginable just a few years ago. Days after tissue collection, the Beacon provides a rich data set about each antibody screened to identify the rare, active, cross-reactive mAbs that are ideal for clinical development.
The Beacon platform is a perfect combination with our ability to generate immune responses in-vivo against difficult-to-target epitopes and our expertise in downstream characterization.
By screening mAbs in for the proper functional activity and cross-reactivity upfront the process is much more efficient than the age-old method of developing and expressing thousands of mAbs to identify the few with relevant function. This results in better mAbs, delivered faster and with less wasted resources.
THE ABVERIS ADVANTAGE:
Best-in-class B-cell screening technology
Advanced immunization capabilities
Extremely rapid timelines
Presented by Colby Souders, PhD, CSO of Abveris and Anupam Singhal, PhD, Antibody Discovery Product Manager at Berkeley Lights.